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Abstract: An unregulated neuroinflammation accompanies numerous chronic and acute neurodegenerative disorders and 
it is postulated that such a neuroinflammatory component likely exacerbates disease progression. A key player in brain 
inflammation is the microglial cell; a vital soluble factor synthesized by activated microglial cells is the key cytokine, 
tumor necrosis factor–alpha (TNF-). Additionally, microglial cells release IL-1/, reactive oxygen species (ROS), such 
as superoxide (O2
-) and reactive nitrogen species (RNS) like nitric oxide (NO). Nitric oxide reactive oxygen species can 
undergo various forms of interactions in cells whereby the synthesis of RNS / ROS intermediates are generated that can 
damage cell membranes. The presence of oxidative damaged cells is implicated with the abnormal cellular activity in 
brain or in the spinal cord, and is a classical feature of neurodegenerative disorders. To aid characterize this process, a 
quantitative analysis of nitrite generation was undertaken on agents developed to lower TNF- levels in cell culture. 
Nitrite is a stable end product of nitric oxide metabolism and, thereby, acts as a surrogate measure of the highly unstable 
nitric oxide. Utilizing a RAW 264.7 cellular model of lipopolysaccharide-induced inflammation that induces high levels 
of TNF- protein accompanied by a robust generation of nitrite, the properties of a series of thalidomide-based TNF- 
synthesis inhibitors were evaluated to reduce the levels of both. Specific analogues of thalidomide effectively suppressed 
the generation of both TNF- and nitrite at well-tolerated doses. 
Keywords: TNF-, nitric oxide, nitrite, RAW 264.7 cells, lipopolysaccharide, thalidomide, revlimid, lenalidomide, 
neuroinflammation. 
INTRODUCTION 
  Alzheimer's disease (AD) is one of the most prevalent 
neurological disorders in humans and, according to recent 
estimates, there are in excess of 27 million people worldwide 
who have been diagnosed with the condition, of which 5 
million reside in North America. Based on data from 
ongoing studies, these numbers are anticipated to increase 
sharply in the near future [1]. Strongly associated with 
several neurological disorders, which include AD, 
Parkinson’s disease (PD) and amyotrophic lateral sclerosis 
(ALS) is the phenomenon of neuroinflammation. It is 
believed that, whereas the specific causes of these conditions 
remain to be fully elucidated, neuroinflammation plays a 
critical role in the neurodegeneration continuum [2-4]. 
  In brain, a key cellular player involved in the immune 
response is the brain resident macrophage, the microglial 
cell; another principle cell is the astrocyte. Typically, 
microglial cells are involved in maintaining the homeostasis 
of the brain microenvironment. These act primarily by 
augmenting the clearance of cellular debris from dead or 
dying cells or responding to pathogens and cytokines 
produced by other immune cells [5, 6]. During normal 
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conditions, microglial cells are described as ‘ramified’ or 
‘resting’, wherein they are essentially dormant, yet standing 
by should they be needed to rapidly respond to any form of 
stimulation. Under potentially pathological conditions, 
however, these resting cells can be induced by exogenous 
and endogenous factors that trigger morphological changes 
which move the cells towards an amoeboid, activated 
morphology. In this activated state, a classical feature is the 
generation of an oxidative burst, or respiratory burst, 
wherein the cells are actively responding to, and 
synthesizing an array of soluble factors. These cellular 
factors, if unregulated, may induce neuronal dysfunction and 
degeneration, or they may transform additional resting 
microglial / astrocyte cells into activated immune cells. Such 
factors include the following: TNF-, IL-1/, reactive 
nitrogen species (RNS), like nitric oxide (NO), and reactive 
oxygen species (ROS), such as superoxide (O2
-). With regard 
to soluble factors released by activated microglial cells, one 
of the most important proteins is TNF- [7, 8]. TNF- 
signaling can be mediated via several pathways. (1) Through 
the c-Jun N-terminal kinase pathway that, depending on 
which transcription factors are activated, may lead to cell 
death or cell survival effects [9-16]. (2) Via the activation of 
a caspase-dependent signaling pathway, which may cause 
apoptotic cell death [17]. (3) Additionally, by TNF- 
activation of the transcription factor NFB, which, in turn, 
induces the activation of survival pathways [18]. Hence, 
TNF- signaling can be associated with both cell death and 
cell survival properties and, consequently, this makes a 38    The Open Biochemistry Journal, 2011, Volume 5  Tweedie et al. 
principle role for TNF- difficult to define for a given set of 
cellular circumstances. Perhaps a key feature of this potent 
pro-inflammatory cytokine is related to the apparent ease 
with which it can activate resting immune cells. This ability 
creates an opportunity to allow the formation of a feedback 
loop of TNF-–induced unregulated neuroinflammation 
[19]. The potential for a feedback phenomenon becomes of 
major relevance in several CNS diseases when one considers 
that in the majority of these medical conditions altered 
cellular states exist in the brain which generate an ideal 
environment for immune cell self-activation, as exemplified 
by amyloid-beta peptide (A) in AD.  
  In AD a hallmark feature, is the formation of the toxic 
peptide A that is generated by the proteolytic actions of 
both - and -secretase on amyloid precursor protein (APP) 
[20]. Both cell culture and animal studies have shown that 
A-peptide can induce the activation of microglial cells, 
following which they can release cytokines and cytotoxic 
factors [21, 22]. Likewise in PD, a cardinal feature is the 
presence of -synuclein (-syn) protein deposits in the brain 
that, in a manner reminiscent of AD, can form -syn 
aggregates [23] and induce the activation of microglia [23-
26]. Lastly, in a subset of ALS patients bearing superoxide 
dismutase (SOD) mutations, defective communication 
between neurons and microglial cells instigates an 
inappropriately exaggerated cytokine release that is capable 
of inducing both ROS and RNS mediated damage to neurons 
within the spinal cord [27-32]. In each scenario, the self-
activation feature of brain glial cells provides a mechanism, 
when it goes awry, that underpins the induction of an 
unregulated neuroinflammatory response [33, 34]. 
Accordingly, it comes as no surprise that elevated levels of 
TNF- protein or the detection of TNF- gene transcripts 
are associated with clinical cases of CNS disorders [2-4, 19]. 
Interventions aimed at limiting the biological signaling 
consequences of TNF- may therefore be beneficial in such 
conditions.  
  This has been shown to be the case in peripheral immune 
related diseases, epitomized by rheumatoid arthritis, Crohn’s 
disease and psoriasis. A successful therapeutic treatment 
approach for these has been the use of protein-based agents 
to sequester free soluble TNF- protein thereby eliminating 
the opportunity for the cytokine to activate its receptors. In 
relation to neurological diseases, a similar approach has been 
taken in proof of concept clinical studies involving AD 
patients, where benefits in specific cognitive features were 
detected shortly after perispinal administration of the TNF- 
sequestering agent, Enbrel (Etanercept), followed by 
Trendelenburg positioning [35, 36]. Agents of this class, 
including Remicade (Infliximab) are large proteins that clear 
released soluble TNF- before it can bind to its receptors; 
thereby, preventing TNF- signaling. Unfortunately such 
protein therapeutics possess limited blood brain-barrier 
penetrability, making their wide utility for neurological 
disorders less than optimal. 
  An alternative approach is to limit the rate of TNF- 
protein synthesis by interfering with the transcription or 
translation of its gene products. This is achievable through 
the use of small drug agents, such as thalidomide (N--
phthalimidoglutarimide). Thalidomide possesses appropriate 
physicochemical characteristics (C log D value) to support 
high blood brain-barrier penetration and brain delivery [37] 
and, by reducing the half-life on TNF- mRNA stability, it 
thereby lowers biosynthesis of this potent cytokine [38]. 
Thalidomide additionally provides a useful pharmacophore 
to support the synthesis and development of feasibly more 
potent and better-tolerated agents. The analogue, 
lenalidomide (Revlimid), represents an example found 
effective in the treatment of multiple myeloma [39, 40], and 
sulfur analogues appear to be particularly effective in 
lowering TNF- [41,42] and may hence have a utility in the 
treatment of neurodegenerative diseases [2].  
  Extending the development of a cellular model of 
inflammation with utility in identifying novel thalidomide 
based TNF- agents [43], herein we describe the use of this 
model to elucidate the actions of compounds on TNF- and 
an end stage product of nitric oxide metabolism, nitrite (NO2
-
) [44]. Gaining insight to the relationship between TNF- 
and NO has become increasingly important consequent to 
the indication that induction of a TNF- response, alone, is 
insufficient to cause neuronal cell death. Occurrence of a 
secondary condition may be required and, in this regard, 
nitric oxide generation may play a vital role in causing TNF-
 mediated neurotoxicity [45]. The present study describes 
the use of a cellular mouse RAW 264.7 cell model of 
inflammation to examine the relationship between LPS 
induced synthesis of TNF- protein and nitrite, a surrogate 
of nitric oxide generation. This allowed analysis of the 
actions of agents with TNF- and nitric oxide lowering 
actions. Accordingly, levels of TNF- protein were 
quantified by use of an ELISA specific for mouse TNF- 
and, to indirectly assess levels of nitric oxide generated by a 
RAW cell oxidative burst, the Griess Reagent System was 
utilized to measure nitrite (NO2
-) [44, 46]. Selected 
thalidomide analogues were able to effectively suppress the 
synthesis of both TNF- and nitrite more effectively than 
thalidomide. 
MATERIALS AND METHODS 
Cellular Proliferation, Nitrite and TNF- Protein Level 
Quantification 
  The CellTiter 96 AQueous One Solution Cell 
Proliferation Assay (Promega, Madison, WI) is routinely 
used as an assay of cell proliferation, and was used herein, 
according to the manufacturer’s recommendations. Changes 
in cellular health status are determined by use of indirect 
measures related to the formation of a colored tetrazolium 
dye product that can be measured spectrophotometrically at 
490 nm . An elevation in absorbance is indicative of an 
increase in cell number and, hence, cellular proliferation. 
Optical densities (expressed as O.D.s) were measured after 1 
to 2 hours incubation. Nitrite levels in the culture media 
were measured by use of the Griess Reagent System 
(Promega, Madison, WI), following the manufacturer’s 
protocol. The O.D. of unknown samples was read at 520 nm 
, compared to a sodium nitrite standard curve (1.5 μM to 
100  μM) and nitrite measured media concentrations 
expressed as μM units. As the lowest nitrite concentration on 
the Griess Reagent System standard curve was 1.5 μM, this 
was chosen as the effective cutoff for defining measurable 
nitrite concentrations. TNF- protein levels were measured 
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(BioLegend, San Diego, CA) and are expressed as a % 
change from their appropriate control or as pg/ml. 
RAW 264.7 Cell Culture 
  RAW 264.7 cells derived from ATCC (Manassas, VA, 
USA) were grown in DMEM media supplemented with 10% 
FCS, penicillin 100 U/ml and streptomycin 100 μg/ml, and 
maintained at 37
oC and 5% CO2. Cells (100 or 200 x 10
3) 
were seeded in 24 well plates and, 24 hours later, were 
utilized in studies. Two hours prior to the initiation of any 
study, the seeding media was replaced with fresh media (1 
ml), and the cells were allowed to equilibrate at 37
oC and 5% 
CO2. 
Lipopolysaccharide-Induced Changes in RAW 264.7 
TNF-, Nitrite Levels and Cell Viability 
  RAW 264.7 cells were challenged with LPS (Sigma, St 
Louis, MO: serotype 055:B5) from 0.1 ng/ml to 200 ng/ml. 
Each concentration was prepared as a 100 times stock 
solution in sterile saline and applied directly to individual 
wells in a 24 well plate. At 24 and 48 hours following the 
addition of LPS, conditioned media was harvested and 
analyzed for quantification of secreted TNF- protein and 
nitrite levels. Fresh media was replaced into the wells and 
cell viability was then assessed. 
Thalidomide and Analogues 
  Thalidomide and analogues were prepared in tissue 
culture grade dimethylsulphoxide (DMSO, Sigma). RAW 
264.7 cells were pretreated with thalidomide, analogues or 
vehicle (at 1:200 dilution in 100% DMSO) one hour prior to 
LPS challenge. The effects of thalidomide and four thio-
thalidomide analogues (Fig. 1) were assessed at 10 μM and 
30 μM concentrations. All were synthesized to a chemical 
purity of >99.5%, as assessed by chemical characterization 
by a combination of 
1H NMR, 
13C NMR and GC/MS 
analyses (Bruker AC-300 spectrometer, together with 
elemental analyses (Atlantic Microlab, Inc., Norcross, GA), 
as previously described [42]. 
Statistical Analyses 
  Data throughout are expressed as means ± standard 
errors, where the n number is shown in parentheses. 
Statistical comparisons were undertaken by use of either a 
Students t-test, or by One Way ANOVA with appropriate 
Bonferroni corrections for multiple comparisons, as required 
(GraphPad InStat Version 3.05). P values of <0.05 are 
considered to be of statistical significance, *, **, *** refers 
to P<0.05, P<0.01 and P<0.001 respectively. 
RESULTS 
TNF- and Nitrite Generation 
  Utilizing optimized RAW 264.7 cell culturing conditions 
initially designed to assess the effects of novel thalidomide 
analogues on LPS-induced TNF- synthesis [43, 44], we 
attempted to measure the levels of nitrite generated over a 24 
hour incubation period, where the cells were challenged with 
a range of LPS concentrations. This experiment indicated 
that the administration of LPS, at concentrations up to 60 
ng/ml for 24 hours, to RAW 264.7 cells seeded at 100 x10
3 
cells per well, failed to induce a measurable level of nitrite 
based on the lower limits of the Griess Reagent System. 
However, under these same conditions a highly significant 
increase in TNF- protein was observed (Fig. 2). The TNF- 
levels detected in the culture media increased markedly in a 
LPS dose-dependent manner, TNF- levels increased from 
484±126 pg/ml for 0.1 ng/ml of LPS up to 11,190±405 
pg/ml for 60 ng/ml LPS. Control (unchallenged) TNF- 
levels were 203±16 pg/ml. There was no evidence of cell 
toxicity as indicated by the MTS assay; exposing RAW cells 
to LPS at concentrations from 0.6 ng/ml and higher caused a 
small but significant increase in cell proliferation (Fig. 2). 
The Griess Reagent System assay indicated that the levels of 
nitrite present in this set of conditioned culture media were 
below 1.5 μM (data not shown). 
  In a subsequent set of experiments in order to optimize 
the cell assay for the measurement of nitrite in culture media 
we: (1) increased the cell seeding density to 200 x10
3 cells 
per well; (2) used higher concentrations of LPS (up to 200 
ng/ml of LPS); and (3) employed longer incubation times. 
After 24 hours incubation with LPS, highly significant 
elevations in both TNF- protein and nitrite were measured 
in culture media (Fig. 3,  Top panel). Specifically, TNF- 
protein levels ranged from 6913±703 pg/ml for 10 ng/ml 
LPS, to 15028±1877 pg/ml for 200 ng/ml LPS. By contrast, 
media from controls unchallenged by LPS demonstrated 
TNF- protein levels of 62±6 pg/ml. The nitrite levels 
ranged from 1.7±0.13 M for 10 ng/ml LPS to 5.7±0.41 M 
 
Fig. (1). The structure of thalidomide and thio-thalidomide 
analogs used in this study are presented: A thalidomide (C logD 
-0.83); B dithioglutarimide (C logD -0.54); C dithiopthalimide (C 
logD 0.72); D 3,6’-dithiothalidomide (C logD -0.86); E 3,2’, 6’-
trithiothalidomide (C logD -0.30). C logD is an index of lipid 
solubility of an agent, negative values indicate a preference for a 
lipid environment.  40    The Open Biochemistry Journal, 2011, Volume 5  Tweedie et al. 
for 200 ng/ml LPS. Elevations in nitrite levels appeared to 
plateau at 130 ng/ml LPS and were similar at LPS 
concentrations thereafter: 5.7±0.20 M and 6.4±0.69 M for 
130 and 160 ng/ml, respectively. By contrast, those in 
control cell media were below the lowest concentration on 
the standard curve (1.5 μM). The MTS assay indicated no 
evidence of cell toxicity at the high levels of LPS used in this 
study. The consequences of a 48 hour incubation of RAW 
264.7 cells, 200 x10
3 cells per well, with LPS on both TNF-
 protein and nitrite generation are presented in Fig. (3) 
(Bottom panel). Specifically, TNF- levels in the media 
were elevated to 3348±59 pg/ml for 10 ng/ml LPS, and 
7070±128 pg/ml for 200 ng/ml LPS, compared to control 
levels of 77±4 pg/ml. Correspondingly, nitrite levels ranged 
from 3.9±0.82 M for 10 ng/ml LPS to 8.4±0.59 M for 200 
ng/ml of LPS. Nitrite concentrations for 130 and 160 ng/ml 
of LPS were 9.4±0.77 and 8.8±1.16 M, respectively. The 
nitrite levels measured in media from the 48 hours 
incubation were significantly higher that those measured 
from the 24 hours time point at corresponding LPS 
concentrations. Similar to prior studies, nitrite levels for 
control wells were below the detection limit of the utilized 
assay and the MTS evaluation indicated a lack of toxicity for 
all LPS concentrations over 48 hours. 
Thalidomide and Analogue Effects on TNF- and Nitrite 
Generation 
  Having characterized the assay conditions, the impact of 
thalidomide and analogues on LPS induced TNF- protein 
and nitrite generation was then examined. At 24 hours 
following plate seeding with 200 x10
3 cells per well, 
pretreatment with thalidomide or analogues (10 or 30 M) 
was initiated, and LPS (60 ng/ml) was added an hour later. 
This LPS concentration was chosen as a submaximal, non-
saturating concentration in relation to TNF- protein and 
nitrite generation responses (see Fig. 3). A submaximal LPS 
concentration was chosen to ensure that in addition to drug-
induced reductions, elevations in TNF- protein and nitrite 
could also be assessed and that both would fall within the 
linear range of the assay. The following agents were utilized: 
thalidomide, dithioglutarimide, 3,6’-dithiothalidomide, 
3,2’,6’-trithiothalidomide, and dithiopthalidomide, together 
with drug vehicle (100% DMSO) that was added to control 
wells. At 24 and 48 hours thereafter, actions on TNF- 
protein synthesis, nitrite generation and cell viability were 
assessed. Evident in Fig. (4) (top panel), assessed at 24 hours 
thalidomide (10 and 30 μM) had no inhibitory action on 
secreted TNF- protein levels when compared to vehicle 
control cells. Likewise, nitrite levels for thalidomide 10 and 
30  M were no different from vehicle values (control: 
2.5±0.05 μM vs. thalidomide 10 and 30 μM: 2.6±0.21 μM 
and 2.2±0.31 μM), and no changes in cell viability were 
observed (Fig. 4, Top panel). In contrast, all thalidomide 
analogues significantly attenuated the LPS-induced rise in 
TNF- protein, and similarly reduced generation of nitrite. 
 
Fig. (2). TNF- protein levels and cell viability after a 24 hour 
incubation period of RAW 264.7 cells (100K cells/well) with 
LPS are presented. TNF- levels (pg/ml) and MTS assay optical 
density (O.D.) values are shown. TNF- protein levels detected in 
the culture media significantly increased in a LPS dose dependent 
manner from 0.1 ng/ml of LPS to 60 ng/ml of LPS. LPS did not 
have any adverse effects on cell viability. Data are presented as 
mean ± S.E.M. of n observations. 
 
Fig. (3). TNF- protein, nitrite levels and cell viability after a 
(TOP) 24 hour and (BOTTOM) 48 hour incubation period of 
RAW 264.7 cells (200K cells/well) with LPS are presented. 
TNF- protein levels (pg/ml); MTS assay optical density (O.D.) 
values and nitrite levels (M) are shown. After 24 hours (TOP) and 
48 hours (BOTTOM) with LPS, 10 ng/ml of LPS to 200 ng/ml of 
LPS, TNF- protein levels and nitrite levels measured in harvested 
media significantly increased in a LPS dose dependent manner. 
Data from the MTS assay showed that higher doses of LPS 
displayed no evidence of cell toxicity. Data are presented as mean ± 
S.E.M. of n observations. Thalidomide Analogues Suppress Lipopolysaccharide-Induced  The Open Biochemistry Journal, 2011, Volume 5    41 
However, reductions in TNF- protein and nitrite for 
specific analogs were associated with a mild loss of cell 
viability. Dithioglutarimide (10 M) proved well-tolerated, 
reduced TNF- protein levels to 58±14 % of controls and, 
likewise, lowered nitrite levels to those comparable with 
control values; from 2.5±0.05 M to below 1.5 μM (drug 
values were 0.46±0.10 M). In the same way, 3,2’,6’-
trithiothalidomide (10 M) lacked toxicity and yet reduced 
TNF- protein levels to 48±2 % of control and nitrite to 
below 1.5 μM, (drug values were 0.03±0.031 M). The other 
thalidomide analogues lowered TNF- protein levels over a 
range spanning 48±1 % to less than 22±1 % of control 
values, nitrite values were similarly reduced below the 1.5 
μM cutoff; however, the agents were associated with 
significant, yet variable degrees of cell loss (Fig. 4, Top 
panel). 
  Following 48 hours incubation, TNF- levels in 
thalidomide (10 and 30 M) treated cells were no different 
from vehicle control values (Fig. 4, Bottom panel). Contrary 
to expectation, thalidomide elevated nitrite generation, 
raising values from 4.6±0.7 μM (control) to 7.5±0.2 μM and 
6.7±0.1  μM at 10 and 30 M thalidomide, respectively. 
Similar to that evident at 24 hours, thalidomide analogues 
proved capable of lowering TNF- protein and nitrite 
generation. In this regard, 3,6’-dithiothalidomide and 
dithiopthalimide at both 10 and 30 M significantly reduced 
TNF- levels. The higher concentration of 30 M 
dithioglutarimide and 3, 2’,6’-trithiothalidomide likewise 
proved able to reduce this cytokine’s level. In relation to 
LPS-induced nitrite, 10 and 30 μM 3,2’,6’-trithiothalidomide 
and dithiopthalimide, and 30 μM dithioglutarimide and 3,6’-
dithiothalidomide significantly lowered generation. Cell 
viability data indicated that thalidomide (10 and 30 M), 
dithioglutarimide, 3,6’-dithiothalidomide and 3,2’,6’-
trithiothalidomide (10 M) were well tolerated. In contrast, 
however, the TNF- protein and nitrite lowering actions of 
all analogues at 30 M were associated with a significant 
reduction in cell viability. 
DISCUSSION 
  The aims of this study were to determine whether novel 
thiol analogues of thalidomide possessed utility at limiting 
the synthesis of TNF- protein and reactive nitrogen species 
induced by LPS in an in vitro cell model of inflammation. 
Based on concentration-matched data described here, we 
extend the prior work of Tweedie et al. [43] and Park et al., 
[44], and demonstrate that thiol analogues of thalidomide, 
but not thalidomide, were able to significantly reduce the 
synthesis of TNF- protein and consequently the generation 
of nitrite in a selective and concentration-dependent manner. 
  The activation of RAW cells by LPS is mediated by the 
following process: LPS interacts with the CD14/TLR-4/MD2 
receptor complex on macrophage / microglial cell surfaces 
and induces the synthesis of many cellular factors, such as 
IL-1/, IL-6, IL-12 and cyclooxygenase-2 (COX-2), 
reactive oxygen / nitrogen species (ROS / RNS) and the 
potent pro-inflammatory protein TNF-. In the current 
study, the biological consequences of RAW cell activation 
by LPS were assessed by measurement of TNF- protein 
levels, a marker routinely measured in our laboratory [43], 
and the levels of a stable end product of nitric oxide 
metabolism, nitrite (NO2
-). TNF- protein interacts with the 
TNF- receptor 1 which regulates NFB activity, ultimately 
allowing the cytoplasmic form of the transcription factor to 
 
 
Fig. 4. The effects of thalidomide analogs on LPS-induced 
alterations in TNF- protein levels, nitrite generation and cell 
viability of RAW 264.7 cells (200K cells/well) after a 24 (TOP) 
and 48 hour (BOTTOM) incubation period with LPS are 
presented. Top panel: 24 hours incubation: TNF- levels (pg/ml), 
MTS assay optical density (O.D.) values and nitrite levels (M) are 
shown. After 24 hours incubation with drugs and LPS, thalidomide 
analogs (but not thalidomide) reduced the levels of TNF- protein. 
Similarly the generation of nitrite was reduced to below vehicle 
control values. Both dithioglutarimide and 3,2’,6’-
trithiothalidomide at 10 μM, presented anti-TNF- and nitrite 
properties with no indication of cell toxicity. The anti-TNF- and 
nitrite actions of 3,6’-dithiothalidomide and dithiopthalimide (10 
μM) were associated with a degree of cell toxicity. All agents at 30 
μM displayed toxicological properties to the RAW cells. Bottom 
panel: After 48 hours incubation with drugs and LPS, comparable 
to that evident at 24 hours the thalidomide analogs, but not 
thalidomide, generated TNF- and nitrite lowering action. 
Interestingly, thalidomide at 10 μM significantly elevated 
generation of nitrite. At 48 hours there was less evidence of cellular 
toxicity induced by several of the thalidomide analogs. Vehicle 
refers to 100% DMSO; TH 10 & 30 refers to thalidomide at 10 and 
30  μM; DT, 3,6’-DT, 3,2’,6’-TRI and Dpth refer to 
dithioglutarimide, 3,6’-dithiothalidomide, 3,2’,6’-trithiothalidomide 
and dithiopthalimide respectively, also at 10 and 30 μM. Data are 
presented as mean ± S.E.M. of n observations. 42    The Open Biochemistry Journal, 2011, Volume 5  Tweedie et al. 
translocate to the nucleus where it can induce a series of 
target genes involved in inflammation, for a review of the 
literature see [47, 48]. Classical target genes activated by 
NFB are: the cytokines that may well have activated the 
NFB pathway (i.e. TNF-), thus introducing a powerful, 
cytokine mediated amplification feedback loop; also 
chemokines and various enzymes such as COX-2, 
phospholipase A2 (PLA2) and inducible nitric oxide 
synthase (iNOS or NOS2). The generation of nitric oxide 
(NO) in macrophage / microglial cells is mediated by the 
actions of iNOS on L-arginine to form NO and citrulline. 
However, NO is highly unstable and has a very short half-
life of approximately 30 seconds; yet, it can undergo rapid 
metabolic transformation with reactive oxygen species (i.e. 
superoxide O2
-) to form the highly neurotoxic peroxynitrite, 
which is associated with cell death [49-51]. 
 As  TNF- signaling is a strong inducer of iNOS–induced 
NO generation that subsequently allows for the interaction of 
ROS with RNS intermediates, events that limit the synthesis 
of TNF- protein would be predicted to most likely limit the 
activation of iNOS and reduce the levels of NO metabolites, 
this was shown to be the case. Thalidomide reduces the half-
life of TNF- mRNA by approximately 50% [38], from 
additional experiments it was subsequently determined that 
thalidomide and the thiol analogues reduced the half-life of 
the mRNA by reducing the RNA stability at the 3’-
untranslated region [41, 52]. However, thalidomide and 
analogues are referred to as immunomodulatory drugs 
(IMIDs) and clearly impact a host of immune markers, in 
addition to those described, both by the defined pathways 
and likely via numerous other primary and secondary ones 
[44, 53-56].  
  As shown in these experimental conditions, the levels of 
measured nitrite are in line with other published reports [44, 
57, 58]. Our nitrite values ranged from 1.7 μM up to ~10 
μM, depending on the specific experimental condition. It is 
important to note that the Greiss Reagent System is used to 
quantify nitrite, and not nitrate, it is highly likely that most 
of our measurements presented here are underestimations of 
the true levels of NO intermediate generation. Indeed, Stuehr 
and Marletta [58] determined that approximately 50 to 75% 
of the LPS-induced macrophage / microglial cell NO is 
converted into nitrite and the remainder to nitrate. Therefore, 
depending on the specific experimental conditions used, our 
measurements may be limited to as much as a 50% 
underestimation on total NO generation. Either way, when 
one considers the implications of these data in light of a 
chronic setting as seen in most CNS neurological conditions, 
it is feasible that quantities of nitric oxide generation, as 
have been reported herein, may be sufficient to induce 
neurodegeneration. 
  Thalidomide has been reported to cause apoptosis in cells 
when used in high concentrations. Such toxicity was not 
evident at the concentrations utilized in our study. It has 
additionally been reported that the mechanism underpinning 
thalidomide-toxicity, as seen in embryonic fibroblasts, is due 
to the generation of ROS namely; superoxide [59]. Hence, it 
is likely that thalidomide per se lacks any inherent 
antioxidant properties. As such, it is feasible to suggest that 
the anti-nitrite properties of the analogues used in this study 
were likely not due to any direct antioxidant properties, but 
due to anti-TNF- mediated effects. Recent studies have 
established that thalidomide’s actions on TNF- are 
multiple, because it has been described to lower TNF- 
under some conditions [38, 60] but not others [61, 62]. In our 
study, thalidomide at concentrations of 10 and 30 μM did not 
significantly alter TNF-, and the lower dose elevated nitrite 
levels, which in accord with Park et al., [44] appeared to be a 
more sensitive marker of thalidomide and analog mediated 
actions. As the thiothalidomide analogs described here can 
attenuate the levels of both TNF- protein and the 
generation of nitrite, a marker of nitric oxide, it is possible 
they may provide a useful form of treatment in unregulated 
CNS neuroinflammatory conditions [2, 19, 26, 33] in 
addition to other disorders [44, 54, 55]. Further evaluation of 
such agents in models of chronic neuroinflammation will be 
required to address this question [63]. 
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